Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corgenix Medical, a developer and marketer of diagnostic test kits, has received notification of two new patents for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan.
Subscribe to our email newsletter
The technology is incorporated in the company’s AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease.
According to the company, the latest patents add to previous US patents which described the specific interaction of B2-glycoprotein I with the oxidized form of low-density lipoprotein (oxLDL) leading to the formation of oxLDL/B2-glycoprotein I complexes (AtherOx). This interaction does not occur with the native or non-oxidized form of LDL.
The most recent patent provides additional coverage to immunoassays for the detection of the oxLDL/B2GPI complexes which is the basis for Corgenix AtherOx test kits, the company said.
Douglass Simpson, president and CEO of Corgenix, said: We are very pleased to announce these important additions to our IP portfolio. We have one AtherOx related product already cleared by the FDA and several products in the later stages of the development pipeline. Since cardiovascular disease is one of the world’s leading causes of death, the early detection of atherosclerosis has become increasingly important, and we are optimistic about our ability to serve this significant market.